- The New Geography of Innovation
- Boston-Cambridge is THE Life Sciences Hub
- Clayton Christensen Demolishes Jill Lepore’s Critique of Disruptive Innovation
- Why isn’t New York City a Biotech Hub?
- Infographic: Top 15 Large Pharma Companies by Market Cap
- Broad Institute Receives $650M for Psychiatric Research
- AbbVie will buy Shire in another Pharma tax inversion strategy
Tag Archives: Pfizer
Taking a page from Pfizer’s playbook, Mylan is buying Abbott Laboratories’ branded specialty and generics businesses in developed markets outside the U.S.. The $5B deal is structured to result in a tax inversion, with the newly formed merged company to be headquartered in the Netherlands. “We see … Continue reading
Pfizer is saying today that it does not intend to extend a firm offer for AstraZeneca, bringing an end to its attempt to acquire the UK drug maker. AZ shareholders were split on the latest offer, and a stumble by AZ would … Continue reading
Over the weekend, Pfizer finally made an official offer for AstraZeneca, by raising its bid to $119B (15% higher than the last, unofficial, offer), and increasing the cash portion of the deal from 33% to 45%. AZ had a market cap of … Continue reading
So says John LaMattina, a former head of research at Pfizer: The only way for a shark to survive is to keep going forward. To maintain its leadership, Pfizer will again need to make a major acquisition in the next … Continue reading
Amidst several indications that Pfizer will launch a hostile bid for AstraZeneca if necessary, this quote stands out: Asked whether hostile moves could hurt integration of the two companies, Chief Executive Ian Read said, “No, in my opinion, all it … Continue reading
Many observers were initially left scratching their heads over Pfizer’s pursuit of AstraZeneca, a company that has had major pipeline troubles of its own. As more information has come out, Pfizer’s strategy is beginning to make sense. They aren’t pursuing an old-style mega … Continue reading
Pfizer continues to stalk AstraZeneca, even as other firms abandon mega mergers.
Here’s more on the Novartis-GSK-Lilly three way deal announced Tuesday. As WSJ journalist Helen Thomas writes, the megamerger chill of dread felt when rumors of Pfizer’s stalking of AZ came to light last weekend may well be exorcized by this … Continue reading